HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system.Continue reading
Author Archive: AZBio
UA Study of Lung Disorders Gets $11.4M Boost
The National Heart, Lung and Blood Institute program has granted $11.4 million to a project led by Dr. Joe G.N. “Skip” Garcia, the UA’s vice president for health sciences.Continue reading
HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).Continue reading
Iron Horse Diagnostics, Inc. Announces License Agreement With Global IVD Powerhouse for First-to-Market ALS Diagnostic Test
Euroimmun granted license to launch first ALS biologic diagnostic test in Europe
Continue reading
Dr Josh LaBaer advances disease research, claims important award
Josh LaBaer, M.D., PhD., a leading researcher in the rapidly expanding field of proteomics, has just been awarded the 2016 Translational Proteomics Award from the Human Proteome Organization (or HUPO). The prestigious award recognizes professor LaBaer’s distinguished scientific achievements in the field of translational proteomics science.Continue reading
Beacon Biomedical Inc. Opens R&D and CLIA Laboratory To Advance Early Cancer Detection Research
Beacon Biomedical, Inc., a privately held company focused on developing highly accurate laboratory and point-of-care blood tests for colorectal cancer screening and its early detection, has opened new Corporate Offices and their R&D-CLIA laboratory at the Center for Entrepreneurial Innovation (CEI) in Phoenix.Continue reading
Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion
Results demonstrate that DecisionDx-Melanoma outcome changed clinical management for over half of tested patients
Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno™ System and Accelerate PhenoTest™ BC kit
Accelerate Diagnostics, Inc. (“Accelerate”) announced today the submission of a De Novo request for Evaluation of Automatic Class III Designation to the U.S. Food and Drug Administration (FDA) for its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood culture samples. Continue reading
UA Health Sciences and Banner Health Receive Historic Funding as part of Landmark Precision Medicine Initiative® Cohort Program
Newly formed network of health-care provider organizations tasked with enrolling U.S. volunteers in a nationwide precision medicine program.Continue reading
RiboMed and Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors
SAN DIEGO – June 6, 2016 – RiboMed Biotechnologies, Inc. and Tocagen Inc., today announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair enzyme O-6-Methylguanine-DNA Methyltransferase (MGMT), in Tocagen’s clinical trials evaluating the investigational treatment Toca 511 & Toca FC in patients with recurrent high grade gliomas (HGGs).Continue reading